- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Darolutamide Plus ADT Elicits OS Benefit in North American Patients With mHSPC
April 29th 2023, 5:12pm
American Urological Association Annual Meeting
A subgroup analysis of the phase 3 ARASENS trial showed that darolutamide plus androgen deprivation therapy elicited an overall survival benefit in North American patients with metastatic hormone-sensitive prostate cancer.
Phase 2 Data Show Clinical Activity With CG0070 Plus Pembrolizumab in NMIBC
April 29th 2023, 4:40pm
American Urological Association Annual Meeting
Cretostimogene grenadenorepvec in combination with pembrolizumab produced high complete response rates with a tolerable safety profile in patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.
Darolutamide Associated With Lower Rates of Treatment Discontinuation and Disease Progression in nmCRPC
April 29th 2023, 3:39pm
American Urological Association Annual Meeting
Treatment with darolutamide was associated with lower rates of discontinuation and progression to metastatic disease compared with enzalutamide and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.
Long-Term JAVELIN Bladder 100 Data Support Avelumab Maintenance in Advanced Urothelial Carcinoma
April 28th 2023, 10:55pm
American Urological Association Annual Meeting
First-line avelumab maintenance therapy prolonged survival in patients with advanced urothelial carcinoma, regardless of response to first-line chemotherapy, according to findings from an exploratory subgroup analysis of the phase 3 JAVELIN Bladder 100 trial.
68Ga-FAP-2286 PET Imaging Influences Bladder Cancer Treatment Decisions
April 28th 2023, 10:10pm
American Urological Association Annual Meeting
The use of 68Ga-FAP-2286 PET imaging may improve treatment selection and response assessment in patients with bladder cancer, according to findings from a pilot study evaluating the diagnostic performance of this imaging technology.
Dr Basin on Pharmacological Inhibition of Hsp70 in Belzutifan-Resistant RCC
April 28th 2023, 10:08pm
American Urological Association Annual Meeting
Michael Basin, MD, discusses how the pharmacological inhibition of the molecular chaperone Hsp70 overcomes belzutifan resistance in clear cell renal cell carcinoma.
Dr Katims on the Utility of the MSK-ACCESS Assay in Node+ MIBC
April 28th 2023, 10:07pm
American Urological Association Annual Meeting
Andrew Katims, MD, MPH, discusses the utility of a circulating tumor DNA assay (MSK-ACCESS) in patients with node-positive muscle-invasive bladder cancer.
Frontline Olaparib Plus Abiraterone Reduces PSA Levels, Delays Time to PSA Progression in mCRPC
April 28th 2023, 7:49pm
American Urological Association Annual Meeting
The addition of olaparib to abiraterone acetate resulted in numerically higher prostate-specific antigen response rates and prolonged time to PSA progression vs abiraterone alone when used in the frontline treatment of patients with metastatic castration-resistant prostate cancer.
Extended Darolutamide Demonstrates Long-term Safety, Clinical Benefit in Nonmetastatic CRPC
April 28th 2023, 7:15pm
American Urological Association Annual Meeting
Darolutamide given in an extended duration was linked with long-term clinical benefit and safety in patients with nonmetastatic castration-resistant prostate cancer.
Apalutamide Dose Reduction Does Not Significantly Reduce Skin-related AEs in Advanced Prostate Cancer
April 28th 2023, 7:10pm
American Urological Association Annual Meeting
Reduced doses of apalutamide did not significantly decrease rates of skin-related adverse effects vs full-dose apalutamide in patients with advanced prostate cancer.
177Lu-PSMA-I&T Generates PSA Responses With Tolerable Safety in mCRPC
April 28th 2023, 6:25pm
American Urological Association Annual Meeting
Treatment with lutetium 177 PSMA-I&T radioligand therapy led to prostate-specific antigen declines with an acceptable toxicity profile in patients with metastatic castration-resistant prostate cancer.
Zoledronic Acid Lowers Risk of Fracture in mHSPC
April 28th 2023, 5:05pm
American Urological Association Annual Meeting
The use of zoledronic acid or other bisphosphonates was associated with a significant reduction in risk of fracture in patients with metastatic hormone-sensitive prostate cancer.
Novel Methylation-Based Platform Shows Promise for Multicancer Early Detection
April 21st 2023, 1:00pm
A genome-wide methylome enrichment platform demonstrated efficacy in detecting early-stage, low-shedding cancers with limited circulating tumor DNA.
Dr Luke on Initial Data From the GLIMMER-01 Trial of E-602 in Advanced Solid Tumors
April 20th 2023, 6:29pm
Jason J. Luke, MD, FACP, discusses initial results from the phase 1 GLIMMER-01 trial of E-602 in advanced solid tumors.
IO-108 Demonstrates Safety and Efficacy in Advanced Solid Tumors
April 19th 2023, 8:03pm
Findings from a phase 1 study showed that the fully humanized IgG4 antibody IO-108 was well tolerated and displayed durable responses when given as a monotherapy as well as in combination with pembrolizumab, supporting further development of the agent alone or with PD-1/PD-L1 targeted therapy for patients with advanced solid tumors.
Dr Skoulidis on the Implications of the POSEIDON Trial of Tremelimumab Plus Durvalumab in NSCLC
April 18th 2023, 9:55pm
Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the clinical implications for data from the combination of tremelimumab plus durvalumab and chemotherapy in metastatic non–small cell lung cancer without sensitizing EGFR mutation or ALK aberrations.
CYCLONE 1 Misses Primary End Point But Abemaciclib Shows Activity in mCRPC
April 18th 2023, 8:55pm
Although the phase 2 CYCLONE 1 trial did not meet its primary end point of overall response rate, treatment with abemaciclib did demonstrate clinical activity among patients with metastatic castration-resistant prostate cancer.
Molecular Analysis Needed to Guide Further Study of Olaparib Plus Ceralasertib in Pediatric Advanced Cancers
April 18th 2023, 8:53pm
The combination of PARP and ATR inhibition with olaparib and ceralasertib was tolerable but showed limited efficacy in pediatric patients with advanced malignancies harboring DNA replication stress and DNA repair deficiencies, according to findings from arm N of the phase 1/2 AcSé-ESMART trial.
Pemigatinib Demonstrates Activity in Previously Treated Solid Tumors Harboring Activating FGFR Alterations
April 18th 2023, 8:30pm
Pemigatinib generated efficacy and tolerability in previously treated patients with advanced/metastatic or unresectable solid tumors harboring activating FGFR mutations or fusions/rearrangements, including cholangiocarcinoma, central nervous system tumors, gynecologic tumors, and pancreatic cancer.
Dr Desai on the Efficacy of Divarasib Plus Cetuximab in KRAS G12C–Mutant CRC
April 18th 2023, 8:23pm
Jayesh Desai, MBBS, FRACP, discusses efficacy data for the combination of divarasib plus cetuximab in patients with colorectal cancer harboring a KRAS G12C mutation from a phase 1B study.